Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANT-060
- Development stage
- Preclinical
- Lead developer
- Antikor Biopharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ANT-060 is a preclinical-stage antibody fragment-drug conjugate (FDC) being developed by Antikor Biopharma for the treatment of solid tumors. Utilizing Antikor's proprietary OptiLink technology platform, ANT-060 is designed to combine the high specificity of miniaturized antibody fragments (such as single-chain variable fragments, or scFvs) with potent cytotoxic payloads. This small-format conjugate approach is engineered to enable rapid and even tumor penetration, high drug-to-antibody ratios (DAR), and fast clearance from normal tissues, thereby expanding the therapeutic index compared to conventional whole-antibody drug conjugates (ADCs).
Beyond the preview
Go deeper on ANT-060.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANT-060.